ML18099A229
| ML18099A229 | |
| Person / Time | |
|---|---|
| Site: | 11006300 |
| Issue date: | 04/06/2018 |
| From: | Owens J E NRC/OIP/ECNP |
| To: | DeLaBarre R US Dept of State, Bureau of International Security & Nonproliferation, US Dept of State, Office of Nuclear Energy Safety & Security Affairs |
| Savoy J M | |
| References | |
| Download: ML18099A229 (1) | |
Text
- UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001 Aprils, 2018 Mr. Robin DeLaBarre Office of Nuclear Energy, Safety & Security Affairs, Room 3320 HST Bureau of International Security& Nonproliferation U.S. Department of State 2201 C Street, NW Washington, D.C. 20520
Dear Mr,
DeLaBarre:
Enclosed is an application (XMAT444), dated January 18, 2018, received by the U.S. Nuclear Regulatory Commission (NRC), from Vertex Pharmaceuticals Incorporated, for the export of 5000 kilograms of deuterium to Esteve Quimica, S.A. in Spain. Vertex plans to utilize the deuterium compounds to manufacture active pharmaceutical ingredients for use in clinical trials on treatments of cystic fibrosis.In accordance with our mutual understandings documented in August 2016, "Processing applications for licenses for exports of deuterium," we would appreciate receiving your judgement as to whether:* The facts of the proposed export are consistent with non-nuclear end use;* The Executive Branch does not see a need for assurances from the recipient government; and* The proposed export would not be inimical to the common defense and security of the United States.Sincerely, Janice E. Owens, Acting Chief Export Controls and Nonproliferation Branch Office of International Programs
Enclosure:
Export License Application cc w/enclosure:
K. Strangis, DOE/NNSA J. Norles, DOE/NNSA M. Shoemaker, NRC/NMSS J. Semones, DHS/CBP S. Aguilar, NRC/NMSS M. Chen, DOE/NNSA P. Dessaules, DOE/NMMSS R. Bennett, DHS/CBP S. Clagett, DOC E. Sauls, DTRA